PETRUSHKA decision-support tool reduced treatment discontinuation and improved symptoms in major depressive disorder

This study was a randomized clinical trial conducted across 47 sites in Brazil, Canada, and the UK. The population consisted of 540 persons between the ages of 18 and 74 years diagnosed with major depressive disorder. Participants were randomized to receive either an evidence-based clinical decision-support system known as the PETRUSHKA tool or usual care. The primary outcome measured was treatment discontinuation due to any cause at 8 weeks. Secondary outcomes included treatment discontinuation up to 24 weeks due to adverse events, changes in depressive symptoms measured by the 9-item Patient Health Questionnaire (PHQ-9), and changes in anxiety symptoms measured by the 7-item Generalized Anxiety Disorder (GAD-7) questionnaire. The follow-up period was 8 weeks for the primary outcome and extended to 24 weeks for secondary outcomes regarding symptom changes.

Regarding the primary outcome, the rate of treatment discontinuation due to any cause at 8 weeks was 41 of 241 participants (17%) in the PETRUSHKA group versus 69 of 252 participants (27%) in the usual care group. The adjusted relative risk was 0.62, with a 95% confidence interval of 0.44 to 0.88 and a P value of .007, indicating a statistically significant decrease in discontinuation for the intervention group. For the secondary outcome of treatment discontinuation due to adverse events at 8 weeks, the rate was 22 of 241 (9%) in the PETRUSHKA group compared with 39 of 252 (16%) in the usual care group. The adjusted relative risk was 0.59, with a 95% confidence interval of 0.36 to 0.97 and a P value of .04.

At 24 weeks, depressive symptoms showed improvement in the PETRUSHKA group. The mean PHQ-9 score was 7.1 (SD, 5.4) in the PETRUSHKA group versus 9.2 (SD, 6.5) in the usual care group. The adjusted between-group mean difference was -1.92, with a 95% confidence interval of -3.06 to -0.78 and a P value less than .001. Anxiety symptoms also improved, with a mean GAD-7 score of 4.6 (SD, 4.1) in the PETRUSHKA group versus 5.8 (SD, 4.9) in the usual care group. The adjusted between-group mean difference was -1.39, with a 95% confidence interval of -2.26 to -0.52 and a P value of .002.

Safety and tolerability were assessed primarily through discontinuation rates. Treatment discontinuation due to adverse events occurred in 9% of the PETRUSHKA group versus 16% of the usual care group at 8 weeks. Serious adverse events were not reported in the study data. Specific tolerability metrics beyond discontinuation were not reported. The study did not provide detailed adverse event profiles beyond the rates leading to discontinuation.

When compared to prior landmark studies in the therapeutic area for major depressive disorder, this trial adds evidence regarding the utility of decision-support systems in reducing early dropout. However, the lack of a double-blind design introduces potential bias, as clinicians and patients in the intervention group may have been influenced by knowledge of the decision-support tool. Additionally, a large amount of missing data was noted as a limitation, which can affect the precision of the estimates and the generalizability of the results.

The key methodological limitations include the lack of a double-blind design and the presence of a large amount of missing data. These factors suggest that the observed benefits, while statistically significant, should be interpreted with caution. The funding source and potential conflicts of interest were not reported, which is a standard transparency issue in clinical research.

Clinically, the use of the PETRUSHKA tool appears to increase the number of patients remaining on their antidepressant medication at 8 weeks and improves depressive and anxiety symptoms at 24 weeks. This suggests that integrating such decision-support tools into practice could help retain patients in treatment and potentially improve symptom outcomes. However, the absence of blinding and missing data means that these results should not be considered definitive proof of efficacy without further corroboration from blinded trials.

Several questions remain unanswered. The long-term sustainability of the symptom improvements beyond 24 weeks is unknown. The specific mechanisms by which the PETRUSHKA tool influences clinician behavior and patient retention require further investigation. Furthermore, the applicability of these findings to settings outside the three countries involved in this trial, or to populations outside the 18 to 74-year age range, has not been established. Future research should aim to address the limitations of blinding and missing data to strengthen the evidence base for this intervention.